The impact of MCCK1, an inhibitor of IKBKE kinase, on acute B lymphocyte leukemia cells.

IF 2.6 4区 工程技术 Q1 Mathematics
Shuangshuang Wen, Peng Zhao, Siyu Chen, Bo Deng, Qin Fang, Jishi Wang
{"title":"The impact of MCCK1, an inhibitor of IKBKE kinase, on acute B lymphocyte leukemia cells.","authors":"Shuangshuang Wen, Peng Zhao, Siyu Chen, Bo Deng, Qin Fang, Jishi Wang","doi":"10.3934/mbe.2024228","DOIUrl":null,"url":null,"abstract":"<p><p>B-cell acute lymphoblastic leukemia (B-ALL) is a malignant blood disorder, particularly detrimental to children and adolescents, with recurrent or unresponsive cases contributing significantly to cancer-associated fatalities. IKBKE, associated with innate immunity, tumor promotion, and drug resistance, remains poorly understood in the context of B-ALL. Thus, this research aimed to explore the impact of the IKBKE inhibitor MCCK1 on B-ALL cells. The study encompassed diverse experiments, including clinical samples, in vitro and in vivo investigations. Quantitative real-time fluorescence PCR and protein blotting revealed heightened IKBKE mRNA and protein expression in B-ALL patients. Subsequent in vitro experiments with B-ALL cell lines demonstrated that MCCK1 treatment resulted in reduced cell viability and survival rates, with flow cytometry indicating cell cycle arrest. In vivo experiments using B-ALL mouse tumor models substantiated MCCK1's efficacy in impeding tumor proliferation. These findings collectively suggest that IKBKE, found to be elevated in B-ALL patients, may serve as a promising drug target, with MCCK1 demonstrating potential for inducing apoptosis in B-ALL cells both in vitro and in vivo.</p>","PeriodicalId":49870,"journal":{"name":"Mathematical Biosciences and Engineering","volume":"21 4","pages":"5164-5180"},"PeriodicalIF":2.6000,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mathematical Biosciences and Engineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3934/mbe.2024228","RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Mathematics","Score":null,"Total":0}
引用次数: 0

Abstract

B-cell acute lymphoblastic leukemia (B-ALL) is a malignant blood disorder, particularly detrimental to children and adolescents, with recurrent or unresponsive cases contributing significantly to cancer-associated fatalities. IKBKE, associated with innate immunity, tumor promotion, and drug resistance, remains poorly understood in the context of B-ALL. Thus, this research aimed to explore the impact of the IKBKE inhibitor MCCK1 on B-ALL cells. The study encompassed diverse experiments, including clinical samples, in vitro and in vivo investigations. Quantitative real-time fluorescence PCR and protein blotting revealed heightened IKBKE mRNA and protein expression in B-ALL patients. Subsequent in vitro experiments with B-ALL cell lines demonstrated that MCCK1 treatment resulted in reduced cell viability and survival rates, with flow cytometry indicating cell cycle arrest. In vivo experiments using B-ALL mouse tumor models substantiated MCCK1's efficacy in impeding tumor proliferation. These findings collectively suggest that IKBKE, found to be elevated in B-ALL patients, may serve as a promising drug target, with MCCK1 demonstrating potential for inducing apoptosis in B-ALL cells both in vitro and in vivo.

IKBKE 激酶抑制剂 MCCK1 对急性 B 淋巴细胞白血病细胞的影响。
B 细胞急性淋巴细胞白血病(B-ALL)是一种恶性血液疾病,对儿童和青少年的危害尤为严重,复发或无反应的病例在癌症相关死亡病例中占很大比例。IKBKE与先天性免疫、肿瘤促进和耐药性有关,但人们对IKBKE在B-ALL中的作用仍然知之甚少。因此,本研究旨在探索 IKBKE 抑制剂 MCCK1 对 B-ALL 细胞的影响。研究涵盖了多种实验,包括临床样本、体外和体内调查。定量实时荧光 PCR 和蛋白质印迹检测显示,B-ALL 患者体内 IKBKE mRNA 和蛋白质表达量增加。随后用 B-ALL 细胞系进行的体外实验表明,MCCK1 处理会导致细胞活力和存活率降低,流式细胞仪显示细胞周期停滞。使用 B-ALL 小鼠肿瘤模型进行的体内实验证实了 MCCK1 在抑制肿瘤增殖方面的功效。这些发现共同表明,B-ALL 患者体内升高的 IKBKE 可能是一个很有前景的药物靶点,MCCK1 在体外和体内都显示出诱导 B-ALL 细胞凋亡的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Mathematical Biosciences and Engineering
Mathematical Biosciences and Engineering 工程技术-数学跨学科应用
CiteScore
3.90
自引率
7.70%
发文量
586
审稿时长
>12 weeks
期刊介绍: Mathematical Biosciences and Engineering (MBE) is an interdisciplinary Open Access journal promoting cutting-edge research, technology transfer and knowledge translation about complex data and information processing. MBE publishes Research articles (long and original research); Communications (short and novel research); Expository papers; Technology Transfer and Knowledge Translation reports (description of new technologies and products); Announcements and Industrial Progress and News (announcements and even advertisement, including major conferences).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信